Department of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA.
Cancer Discov. 2013 Jun;3(6):607-9. doi: 10.1158/2159-8290.CD-13-0185.
Through a clinical deep sequencing protocol, Wu and colleagues have identified multiple FGFR fusion proteins in diverse cancers. Pharmacologic inhibition of FGFR suppressed the growth of FGFR fusion-positive tumor models, suggesting that these FGFR fusions are oncogenic drivers and highlighting the use of streamlined clinical sequencing efforts to identify novel, actionable driver oncoproteins in human tumors.
通过临床深度测序方案，Wu 及其同事在多种癌症中鉴定出多种 FGFR 融合蛋白。FGFR 的药理抑制抑制了 FGFR 融合阳性肿瘤模型的生长，表明这些 FGFR 融合是致癌驱动因素，并强调了简化临床测序工作以鉴定人类肿瘤中新型可操作的驱动致癌蛋白的应用。
